• Proceedings of the PSK Conference
• /
• 2001.10a
• /
• pp.264.3-265
• /
• 2001

• IMMUNE NETWORK
• /
• v.2 no.2
• /
• pp.115-124
• /
• 2002

Background: The chemical characteristics of the exo-secretion from Phellinus linteus (referred to as exo-secretion) including the compositions of amino acids and monosaccharides were investigated. In addition, cytotoxicity of the exo-secretion on 5 tumor cell lines derived from human cancers and its antitumor activity against ascitic sarcoma-180 cells were examined. Methods: The antitumor activity of exo-secretion from Phellinus linteus was determined by measuring parameters including tumor weight, life span of mice, chemotatic activity of leukocytes, counts of immune cells, and activity of cytokines. Results: The exo-secretion from Phellinus linteus showed no direct cytotoxicity to the five tumor cell lines tested, but it had a strong antitumor activity against sarcoma-180 cells in ICR mice as measured by tumor weight and life span of mice. The exo-secretion stimulated the chemotaxis of leukocytes and production of immune cells and cytokines. Conclusion: These results suggest that the exo-secretion from Phellinus linteus do not act as a direct cytotoxic substance to cancer cells but as an immunomodulator.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.21 no.1
• /
• pp.1-11
• /
• 2018

The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have led to the identification of early Crohn's disease and development of the concept of catching the therapeutic window during the early disease course. Thus, an increasing number of pediatric gastroenterologists are adopting an early biologic treatment strategy with or without an immunomodulator. Although early biologic treatment is effective, cost and overtreatment are issues that limit its early use. Currently, there are insufficient data on who will benefit most from early biologics, as well as on who will not need early or even any biologics. For now, top-down biologics should be considered for patients with currently known high-risk factors of poor outcomes. For other patients, close, objective monitoring and accelerating the step-up process by means of a treat-to-target approach seems the best way to catch the therapeutic window in early pediatric Crohn's disease. The individual benefits of immunomodulator addition during early biologic treatment should be weighed against its risks and decision on early combination treatment should be made after comprehensive discussion with each patient and guardian.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.21 no.4
• /
• pp.329-335
• /
• 2018

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.

• Archives of Pharmacal Research
• /
• v.28 no.8
• /
• pp.892-896
• /
• 2005

In order to isolate substances that inhibit the hemolytic activity of human serum against eryth-rocytes, we have evaluated whole plants of the Orostachys japonicus species with regard to its anti-complement activity, and have identified its active principles following activity-guided isolation. A methanol extract of the O. japonicus, as well as its n-hexane soluble fraction, exhibited significant anti-complement activity on the complement system, which was expressed as total hemolytic activity. A bioassay-guided chromatographic separation of the constituents resulted in the isolation of three known compounds 1-3 from the active n-hexane fraction. The structure of these compounds were analyzed, and they were identified as hydroxyhopanone (1), $\beta-sitosteryl-3-O-\beta-D-glucopyranosyl-6'-O-palmitate$ (2), and $\beta-sitosteryl-3-O-\beta-D-glucopyranoside$ (3), respectively. Of these compounds, compound 2 exhibited potent anti-complement activity $(IC_{50}=1.0\pm0.1{\mu}M)$ on the classical pathway of the complement, as compared to tiliroside $(IC_{50}=76.5\pm1.1{\mu}M)$, which was used as a positive control. However, compounds 1 and 3 exhibited no activity in this system.

• Archives of Pharmacal Research
• /
• v.25 no.4
• /
• pp.493-499
• /
• 2002

We investigated the antitumor activity of oregonin, a diarylheptanoid derivative purified from Alnus hirsuta Turcz, Betulaceae. Oregonin is a potential novel immunomodulator, which augments the activation of natural killer (NK) cells, and thereby leads to a powerful antitumor activity. To evaluate the cytotoxicity of oregonin against tumor cells, we examined the effectiveness of NK cells and determined that oregonin could increase NK cell cytotoxicity. This was confirmed by MTT assay. In addition, the survival time of C57BL/6 mice were measured by inoculating 816-F10 melanoma cells to mice via intra muscular (i.m.) injection. Oregonin treatment after 10 hours of inoculation at 10 mg/kg dosage showed a significant extension of survival time by up to 51.32%, when compared to the control group. Moreover, oregonin significantly reduced the incidence of pulmonary metastasis, which may be developed from 816-F10 melanoma cells. These findings suggest that oregon in may be classified as a new and novel immunomodulator due to its potential antitumor activity.

• Journal of Animal Science and Technology
• /
• v.53 no.5
• /
• pp.409-418
• /
• 2011

This study was conducted to investigate the effects of dietary probiotics and immunomodulator on growth performance, carcass characteristics, fecal $NH_3$ content and pathogenic bacteria counts in ileum and cecum and ileum of broiler chicken (Korean native chicken, HanHyup No. 3). A total of 120 (day-old) chicks were randomly divided into 5 treatments with 3 replicates and there were 8 birds per replicate. Dietary treatments consisted of five diets; the corn-soybean based control diet (C), the diet containing antibiotics (Avilamycin) 10 ppm (T1), the diet containing probiotics 1 [(Lactobacillus ($4.45{\times}10^6$) + yeast ($1.51{\times}10^6$) + Bacillus subtilis ($3.50{\times}10^5$)] at 0.5% level (T2), probiotics 2 [(Lactobacillus ($6.70{\times}10^7$) + yeast ($3.10{\times}10^6$)] at 0.5% level in diet (T3), and the diet containing probiotics 3 [T2 + ${\beta}$-glucan + organic acid] (T4) and raised for 9 weeks. There were no significant differences among treatments in weight gain, feed intake and feed conversion. Carcass ratios of broilers were higher in T3 and T4 than other treatments, however, the differences were non-significant. Internal organs and liver, heart weight were significantly increased in T4 (p<0.05) compared to other treatments. The fecal $NH_3$ gas content was decreased (p<0.05) in antibiotics fed group than others. However, probiotic fed groups were not different when compared with control. The number of Salmonella and E. coli in cecum were reduced in the group supplemented with probiotics and immunomodulator compared to the antibiotics (p<0.05). In this experiment, we showed that diets containing pro-biotics and immunomodulator were capable of an alternative to antibiotics.

• Journal of Mushroom
• /
• v.6 no.1
• /
• pp.1-12
• /
• 2008

Mushroom is well known for a safe food for a long time and, what is more, has a lot of useful characteristics related on the pharmacological activities. It is expected to be one of the most important functional food due to its diverse bioactive compounds. Especially, medical potentiality on immunomodulator and antitumor continues to be focused. Recent research trend and commercialization of functional healthy food using mushroom and its bioactive compounds will be herein introduced. Industrialization of mushroom functional substances will be also discussed.

• Proceedings of the Microbiological Society of Korea Conference
• /
• 2007.05a
• /
• pp.140-140
• /
• 2007

• Proceedings of the Korean Society of Life Science Conference
• /
• 2006.09a
• /
• pp.60.2-60.2
• /
• 2006